In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion

被引:28
|
作者
do Vale Morais, Andreza Rochelle [1 ,3 ]
Silva, Andre Leandro [2 ,3 ,6 ]
Cojean, Sandrine [4 ]
Balaraman, Kaluvu [4 ,5 ]
Bories, Christian [4 ]
Pomel, Sebastien [4 ]
Barratt, Gillian [3 ]
Tabosa do Egito, Eryvaldo Socrates [1 ,2 ]
Loiseau, Philippe M. [4 ]
机构
[1] Univ Fed Rio Grande do Norte UFRN, Programa Posgrad Nanotecnol Farmaceut, Rua Gustavo Cordeiro de Farias SN, BR-59012570 Natal, RN, Brazil
[2] Univ Fed Rio Grande do Norte, Programa Posgrad Biotecnol RENORBIO, Ave Senador Salgado Filho,3000 Campus Univ, BR-59078970 Natal, RN, Brazil
[3] Univ Paris Sud, Inst Galien Paris Sud, UMR CNRS 8612, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France
[4] Univ Paris Sud, Fac Pharm, UMR CNRS BioCIS 8076, Chatenay Malabry, France
[5] IITM, Dept Biotechnol, Biol Chem Lab, Technol Madras, Madras, Tamil Nadu, India
[6] UFOB, Ctr Ciencias Biol & Saude, R Prof Jose Seabra de Lemos 316, BR-47808021 Barreiras, BA, Brazil
关键词
Visceral leishmaniasis; Amphotericin B; Microemulsion; Superaggregates; PHOSPHOLIPID-BASED MICROEMULSION; VISCERAL LEISHMANIASIS; DELIVERY-SYSTEM; DEOXYCHOLATE FUNGIZONE; INDUCED REFORMULATION; THERAPEUTIC-EFFICACY; ORAL DELIVERY; TOXICITY; DONOVANI; LIPOSOMES;
D O I
10.1016/j.exppara.2018.07.017
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Amphotericin B (AmB) is effective against visceral leishmaniasis (VL), but the renal toxicity of the conventional form, mixed micelles with deoxycholate (M-AmB), is often dose-limiting, while the less toxic lipid-based formulations such as AmBisome (R) are very expensive. Two different strategies to improve the therapeutic index of AmB with inexpensive ingredients were evaluated on this work: (i) the heat treatment of the commercial formulation (H-AmB) and (ii) the preparation of an AmB-loaded microemulsion (ME-AmB). M-AmB was heated to 70 degrees C for 20 min. The resulting product was characterized by UV spectrophotometry and circular dichroism, showing super-aggregates formation. ME-AmB was prepared from phosphate buffer pH 7.4, Tween 80 (R), Lipoid S100 (R) and Mygliol 812 (R) with AmB at 5 mg/mL. The droplet size, measured by dynamic light scattering, was about 40 nm and transmission electron microscopy confirmed a spherical shape. Rheological analysis showed low viscosity and Newtonian behavior. All the formulations were active in vitro and in vivo against Leishmania donovani (LV9). A selectivity index (CC50 on RAW/IC50 on LV9) higher than 10 was observed for ME-AmB, H-AmB and AmBisome (R). Furthermore, no important in vivo toxicity was observed for all the samples. The in-vivo efficacy of the formulations after IV administration was evaluated in Balb/C mice infected with LV9 (three doses of 1 mg/kg AmB) and no significant difference was observed between H-AmB, M-AmB, ME-AmB and AmBisome (R). In conclusion, these two inexpensive alternative formulations for AmB showing good efficacy and selectivity for Leishmania donovani merit further investigation.
引用
收藏
页码:85 / 92
页数:8
相关论文
共 50 条
  • [31] A rapid and simple preparation of amphotericin B-loaded bacterial magnetite nanoparticles
    Correa, Tarcisio
    Bazylinski, Dennis A.
    Garcia, Flavio
    Abreu, Fernanda
    RSC ADVANCES, 2021, 11 (45) : 28000 - 28007
  • [32] Amphotericin B and its lipid formulations
    Ritter, J
    MYCOSES, 2002, 45 : 34 - 38
  • [33] Pharmacology of lipid formulations of amphotericin B
    Dix, SP
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1998, 7 : S8 - S15
  • [34] Characterization of amphotericin B liposome formulations
    Manosroi, A
    Kongkaneramit, L
    Manosroi, J
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2004, 30 (05) : 535 - 543
  • [35] Amphotericin B formulations and drug targeting
    Torrado, J. J.
    Espada, R.
    Ballesteros, M. P.
    Torrado-Santiago, S.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (07) : 2405 - 2425
  • [36] Overview of the lipid formulations of amphotericin B
    Dupont, B
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 : 31 - 36
  • [37] Preparation, development and in vitro release evaluation of amphotericin B-loaded amphiphilic block copolymer vectors
    Pippa, Natassa
    Mariaki, Maria
    Pispas, Stergios
    Demetzos, Costas
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2014, 473 (1-2) : 80 - 86
  • [38] Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an In Vitro Model of Invasive Pulmonary Aspergillosis
    Lestner, Jodi M.
    Howard, Susan J.
    Goodwin, Joanne
    Gregson, Lea
    Majithiya, Jayesh
    Walsh, Thomas J.
    Jensen, Gerard M.
    Hope, William W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (08) : 3432 - 3441
  • [39] The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole
    Ohtsuka, K
    Watanabe, M
    Orikasa, Y
    Inouye, S
    Uchida, K
    Yamaguchi, H
    Kondo, S
    Takeuchi, T
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (01) : 71 - 77
  • [40] Improved antifungal activity of amphotericin B-loaded TPGS-b-(PCL-ran-PGA) nanoparticles
    Tang, Xiaolong
    Jiao, Ronghong
    Xie, Chunmei
    Xu, Lifa
    Huo, Zhen
    Dai, Jingjing
    Qian, Yunyun
    Xu, Weiwen
    Hou, Wei
    Wang, Jiang
    Liang, Yong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (04): : 5150 - 5162